Drug targeting of sphingolipid metabolism: Sphingomyelinases and ceramidases

British Journal of Pharmacology

Volumn 163, Issue 4, 2011, Pages 694-712

  Canals, Daniel ^a   Perry, David M ^a   Jenkins, Russell W ^a   Hannun, Yusuf A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ceramidase; ceramidase inhibitor; ceramide; sphingolipid; sphingomyelinase; sphingomyelinase inhibitor; therapeutic development

Indexed keywords

ACID CERAMIDASE; ALKALINE CERAMIDASE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CERAMIDASE; CERAMIDASE INHIBITOR; CHLOROQUINE; CHLORPROMAZINE; DESIPRAMINE; ENZYME INHIBITOR; FANTOFARONE; GASTROINTESTINAL AGENT; GW 4869; IMIPRAMINE; LCL 204; LCL 385; MANUMYCIN A; N OLEOYLETHANOLAMINE; NEUTRAL CERAMIDASE; PHOSPHATIDYLINOSITIDE; SCYPHOSTATIN; SMA 7; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; UNDECYLIDENE AMINOGUANIDINE; UNINDEXED DRUG; ZOLEDRONIC ACID;

COLITIS; CYSTIC FIBROSIS; CYTOLOGY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; LIPID METABOLISM; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; CERAMIDASES; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; SPHINGOLIPIDS; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 79958052481     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01279.x     Document Type: Review

References (196)

1. Adam D, Wiegmann K, Adam-Klages S, Ruff A, Kronke M, (1996). A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway. J Biol Chem 271: 14617-14622. (Pubitemid 26190369)
2. Adam-Klages S, Adam D, Wiegmann K, Struve S, Kolanus W, Schneider-Mergener J, et al,. (1996). FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 86: 937-947. (Pubitemid 26336798)
3. Adamy C, Mulder P, Khouzami L, Andrieu-abadie N, Defer N, Candiani G, et al,. (2007). Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol 43: 344-353. (Pubitemid 47301939)
4. Aguilar PS, Frohlich F, Rehman M, Shales M, Ulitsky I, Olivera-Couto A, et al,. (2010). A plasma-membrane E-MAP reveals links of the eisosome with sphingolipid metabolism and endosomal trafficking. Nat Struct Mol Biol 17: 901-908.
5. Albouz S, Hauw JJ, Berwald-Netter Y, Boutry JM, Bourdon R, Baumann N, (1981). Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 35: 218-220. (Pubitemid 12050793)
6. Alphonse G, Bionda C, Aloy MT, Ardail D, Rousson R, Rodriguez-Lafrasse C, (2004). Overcoming resistance to gamma-rays in squamous carcinoma cells by poly-drug elevation of ceramide levels. Oncogene 23: 2703-2715. (Pubitemid 38586324)
7. Amtmann E, Zoller M, (2005). Stimulation of CD95-induced apoptosis in T-cells by a subtype specific neutral sphingomyelinase inhibitor. Biochem Pharmacol 69: 1141-1148. (Pubitemid 40417485)
8. Amtmann E, Zoller M, Schilling G, (2000). Neutral sphingomyelinase- inhibiting guanidines prevent herpes simplex virus-1 replication. Drugs Exp Clin Res 26: 57-65. (Pubitemid 30352885)
9. Amtmann E, Baader W, Zoller M, (2003). Neutral sphingomyelinase inhibitor C11AG prevents lipopolysaccharide-induced macrophage activation. Drugs Exp Clin Res 29: 5-13. (Pubitemid 36818531)
10. Archimandriti DT, Dalavanga YA, Cianti R, Bianchi L, Manda-Stachouli C, Armini A, et al,. (2009). Proteome analysis of bronchoalveolar lavage in individuals from Metsovo, nonoccupationally exposed to asbestos. J Proteome Res 8: 860-869.
11. Arenz C, (2010). Small molecule inhibitors of acid sphingomyelinase. Cell Physiol Biochem 26: 1-8.
12. Arenz C, Giannis A, (2000). Synthesis of the first selective irreversible inhibitor of neutral sphingomyelinase. Angew Chem Int Ed Engl 39: 1440-1442. (Pubitemid 30317581)
13. Arenz C, Gartner M, Wascholowski V, Giannis A, (2001a). Synthesis and biochemical investigation of scyphostatin analogues as inhibitors of neutral sphingomyelinase. Bioorg Med Chem 9: 2901-2904.
14. Arenz C, Thutewohl M, Block O, Waldmann H, Altenbach HJ, Giannis A, (2001b). Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase. Chembiochem 2: 141-143. (Pubitemid 33722539)
15. Auge N, Nikolova-Karakashian M, Carpentier S, Parthasarathy S, Negre-Salvayre A, Salvayre R, et al,. (1999). Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 274: 21533-21538.
16. Azuma N, O'Brien JS, Moser HW, Kishimoto Y, (1994). Stimulation of acid ceramidase activity by saposin D. Arch Biochem Biophys 311: 354-357. (Pubitemid 24220155)
17. Bai A, Szulc ZM, Bielawski J, Mayroo N, Liu X, Norris J, et al,. (2009). Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem 17: 1840-1848.
18. el Bawab S, Mao C, Obeid LM, Hannun YA, (2002). Ceramidases in the regulation of ceramide levels and function. Subcell Biochem 36: 187-205.
19. Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E, (2010). Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42: 716-724.
20. Bernardo K, Hurwitz R, Zenk T, Desnick RJ, Ferlinz K, Schuchman EH, et al,. (1995). Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem 270: 11098-11102.
21. Bernier M, Kwon YK, Pandey SK, Zhu TN, Zhao RJ, Maciuk A, et al,. (2006). Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem 281: 2551-2561. (Pubitemid 43845715)
22. Bielawska A, Greenberg MS, Perry D, Jayadev S, Shayman JA, McKay C, et al,. (1996). 1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem 271: 12646-12654.
23. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, et al,. (2008). Novel analogs of d-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem 16: 1032-1045. (Pubitemid 351163040)
24. Brann AB, Scott R, Neuberger Y, Abulafia D, Boldin S, Fainzilber M, et al,. (1999). Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. J Neurosci 19: 8199-8206. (Pubitemid 30226739)
25. Brann AB, Tcherpakov M, Williams IM, Futerman AH, Fainzilber M, (2002). Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase. J Biol Chem 277: 9812-9818. (Pubitemid 34968085)
26. Callahan JW, Jones CS, Davidson DJ, Shankaran P, (1983). The active site of lysosomal sphingomyelinase: evidence for the involvement of hydrophobic and ionic groups. J Neurosci Res 10: 151-163. (Pubitemid 14231903)
27. Canals D, Jenkins RW, Roddy P, Hernandez-Corbacho MJ, Obeid LM, Hannun YA, (2010). Differential effects of ceramide and sphingosine-1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane. J Biol Chem 285: 32476-32485.
28. Chavez JA, Holland WL, Bar J, Sandhoff K, Summers SA, (2005). Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem 280: 20148-20153. (Pubitemid 41379546)
29. Choi MS, Anderson MA, Zhang Z, Zimonjic DB, Popescu N, Mukherjee AB, (2003). Neutral ceramidase gene: role in regulating ceramide-induced apoptosis. Gene 315: 113-122. (Pubitemid 37214903)
30. Clarke CJ, Snook CF, Tani M, Matmati N, Marchesini N, Hannun YA, (2006). The extended family of neutral sphingomyelinases. Biochemistry 45: 11247-11256. (Pubitemid 44453973)
31. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, Castaneda J, et al,. (2009). Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 82: 296-302.
32. Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S, (1998). Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during fas- and ceramide-mediated apoptosis in jurkat T lymphocytes. J Biol Chem 273: 2910-2916. (Pubitemid 28133941)
33. Dawson G, Qin J, (2011). Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochem Biophys Res Commun 404: 321-323.
34. Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G, (2006). Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 1758: 1957-1977. (Pubitemid 44879369)
35. Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G, (2007). Chemical tools to investigate sphingolipid metabolism and functions. ChemMedChem 2: 580-606.
36. Duan RD, Nilsson A, (2009). Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog Lipid Res 48: 62-72.
37. Duan RD, Verkade HJ, Cheng Y, Havinga R, Nilsson A, (2007). Effects of bile diversion in rats on intestinal sphingomyelinases and ceramidase. Biochim Biophys Acta 1771: 196-201. (Pubitemid 46210190)
38. Dulaney JT, Milunsky A, Sidbury JB, Hobolth N, Moser HW, (1976). Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. J Pediatr 89: 59-61.
39. El Bawab S, Bielawska A, Hannun YA, (1999). Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain. J Biol Chem 274: 27948-27955.
40. El Bawab S, Roddy P, Qian T, Bielawska A, Lemasters JJ, Hannun YA, (2000). Molecular cloning and characterization of a human mitochondrial ceramidase. J Biol Chem 275: 21508-21513. (Pubitemid 30481855)
41. El Bawab S, Birbes H, Roddy P, Szulc ZM, Bielawska A, Hannun YA, (2001). Biochemical characterization of the reverse activity of rat brain ceramidase. A CoA-independent and fumonisin B1-insensitive ceramide synthase. J Biol Chem 276: 16758-16766.
42. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, et al,. (2006). New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 580: 4751-4756. (Pubitemid 44189397)
43. Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, et al,. (2007). Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 15: 1259-1263. (Pubitemid 46965321)
44. Ferlinz K, Kopal G, Bernardo K, Linke T, Bar J, Breiden B, et al,. (2001). Human acid ceramidase: processing, glycosylation, and lysosomal targeting. J Biol Chem 276: 35352-35360.
45. Filosto S, Castillo S, Danielson A, Franzi L, Khan E, Kenyon N, et al,. (2011). Neutral Sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury. Am J Respir Cell Mol Biol 44: 350-360.
46. Franzen R, Pautz A, Brautigam L, Geisslinger G, Pfeilschifter J, Huwiler A, (2001). Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem 276: 35382-35389.
47. Furlong SJ, Ridgway ND, Hoskin DW, (2008). Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. Int J Oncol 32: 537-544. (Pubitemid 351330459)
48. Galadari S, Wu BX, Mao C, Roddy P, El Bawab S, Hannun YA, (2006). Identification of a novel amidase motif in neutral ceramidase. Biochem J 393: 687-695. (Pubitemid 43163808)
49. Gangoiti P, Camacho L, Arana L, Ouro A, Granado MH, Brizuela L, et al,. (2010). Control of metabolism and signaling of simple bioactive sphingolipids: implications in disease. Prog Lipid Res 49: 316-334.
50. Gatt S, (1963). Enzymic hydrolysis and synthesis of ceramides. J Biol Chem 238: 3131-3133.
51. Grijalvo S, Bedia C, Triola G, Casas J, Llebaria A, Teixido J, et al,. (2006). Design, synthesis and activity as acid ceramidase inhibitors of 2-oxooctanoyl and N-oleoylethanolamine analogues. Chem Phys Lipids 144: 69-84. (Pubitemid 44537272)
52. Gulbins E, Li PL, (2006). Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol 290: R11-R26.
53. Hannun YA, Obeid LM, (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150. (Pubitemid 351158911)
54. Hannun YA, Loomis CR, Merrill AH, Jr, Bell RM, (1986). Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 261: 12604-12609. (Pubitemid 17213985)
55. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, et al,. (1993). Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci U S A 90: 2281-2285. (Pubitemid 23078610)
56. Hara S, Nakashima S, Kiyono T, Sawada M, Yoshimura S, Iwama T, et al,. (2004). Ceramide triggers caspase activation during gamma-radiation-induced apoptosis of human glioma cells lacking functional p53. Oncol Rep 12: 119-123.
57. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, et al,. (2004). Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55: 257-267. (Pubitemid 38167003)
58. He X, Okino N, Dhami R, Dagan A, Gatt S, Schulze H, et al,. (2003). Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem 278: 32978-32986. (Pubitemid 37055742)
59. Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, et al,. (2008). Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 61: 231-242. (Pubitemid 350160321)
60. Horton JW, (1999). Tumor necrosis factor-alpha, sphingosine, ceramide: which is the appropriate marker of inflammation? Crit Care Med 27: 2580-2581.
61. Hu W, Xu R, Sun W, Szulc ZM, Bielawski J, Obeid LM, et al,. (2010). Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis. J Biol Chem 285: 7964-7976.
62. Hurwitz R, Ferlinz K, Sandhoff K, (1994). The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375: 447-450. (Pubitemid 2120332)
63. Huwiler A, Pfeilschifter J, (2006). Altering the sphingosine-1-phosphate/ ceramide balance: a promising approach for tumor therapy. Curr Pharm Des 12: 4625-4635. (Pubitemid 44835150)
64. Hwang YH, Tani M, Nakagawa T, Okino N, Ito M, (2005). Subcellular localization of human neutral ceramidase expressed in HEK293 cells. Biochem Biophys Res Commun 331: 37-42. (Pubitemid 40545138)
65. Inoue T, Okino N, Kakuta Y, Hijikata A, Okano H, Goda HM, et al,. (2009). Mechanistic insights into the hydrolysis and synthesis of ceramide by neutral ceramidase. J Biol Chem 284: 9566-9577.
66. Jaffrezou JP, Herbert JM, Levade T, Gau MN, Chatelain P, Laurent G, (1991). Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. J Biol Chem 266: 19858-19864. (Pubitemid 21908305)
67. Jana A, Pahan K, (2004). Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 24: 9531-9540. (Pubitemid 39441507)
68. Jenkins RW, Canals D, Hannun YA, (2009). Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 21: 836-846.
69. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA, (2001). Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 167: 3773-3784. (Pubitemid 32910823)
70. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, et al,. (2008). Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 111: 4716-4722.
71. Koch J, Gartner S, Li CM, Quintern LE, Bernardo K, Levran O, et al,. (1996). Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease. J Biol Chem 271: 33110-33115.
72. Kolesnick RN, (1987). 1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells. J Biol Chem 262: 16759-16762. (Pubitemid 18019025)
73. Kolzer M, Arenz C, Ferlinz K, Werth N, Schulze H, Klingenstein R, et al,. (2003). Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol Chem 384: 1293-1298. (Pubitemid 37168697)
74. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, et al,. (2010). Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 26: 9-20.
75. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, et al,. (2007). Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 282: 16718-16728. (Pubitemid 47093220)
76. Kupchak BR, Garitaonandia I, Villa NY, Smith JL, Lyons TJ, (2009). Antagonism of human adiponectin receptors and their membrane progesterone receptor paralogs by TNFalpha and a ceramidase inhibitor. Biochemistry 48: 5504-5506.
77. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, et al,. (2007). Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 13: 164-170.
78. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, et al,. (2004). Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164: 123-131. (Pubitemid 38082463)
79. Lepine S, Lakatos B, Courageot MP, Le Stunff H, Sulpice JC, Giraud F, (2004). Sphingosine contributes to glucocorticoid-induced apoptosis of thymocytes independently of the mitochondrial pathway. J Immunol 173: 3783-3790. (Pubitemid 39280740)
80. Levade T, Vidal F, Vermeersch S, Andrieu N, Gatt S, Salvayre R, (1995). Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway. Biochim Biophys Acta 1258: 277-287.
81. Li CM, Hong SB, Kopal G, He X, Linke T, Hou WS, et al,. (1998). Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics 50: 267-274. (Pubitemid 28303521)
82. Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, et al,. (2002). Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79: 218-224.
83. Linke T, Wilkening G, Lansmann S, Moczall H, Bartelsen O, Weisgerber J, et al,. (2001a). Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol Chem 382: 283-290. (Pubitemid 32243936)
84. Linke T, Wilkening G, Sadeghlar F, Mozcall H, Bernardo K, Schuchman E, et al,. (2001b). Interfacial regulation of acid ceramidase activity. Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins. J Biol Chem 276: 5760-5768.
85. Lister MD, Ruan ZS, Bittman R, (1995). Interaction of sphingomyelinase with sphingomyelin analogs modified at the C-1 and C-3 positions of the sphingosine backbone. Biochim Biophys Acta 1256: 25-30.
86. Liu B, Hannun YA, (1997). Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272: 16281-16287. (Pubitemid 27276449)
87. Liu B, Hassler DF, Smith GK, Weaver K, Hannun YA, (1998). Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain. J Biol Chem 273: 34472-34479. (Pubitemid 29008927)
88. Liu G, Wang W, Sun G, Ma X, Liu Z, Yang J, (2008). Nystatin interferes with the effects of N-methyl-N'-nitro-N-nitrosoguanidine on sphingolipid metabolism in human FL cells. Lipids 43: 867-875.
89. Llacuna L, Mari M, Garcia-Ruiz C, Fernandez-Checa JC, Morales A, (2006). Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology 44: 561-572. (Pubitemid 44433712)
90. Lozano J, Morales A, Cremesti A, Fuks Z, Tilly JL, Schuchman E, et al,. (2001). Niemann-Pick Disease versus acid sphingomyelinase deficiency. Cell Death Differ 8: 100-103.
91. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, et al,. (2002). Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277: 41128-41139. (Pubitemid 35215704)
92. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, et al,. (2009). Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 17: 430-438.
93. Mao C, Obeid LM, (2008). Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta 1781: 424-434.
94. Mao C, Xu R, Szulc ZM, Bielawska A, Galadari SH, Obeid LM, (2001). Cloning and characterization of a novel human alkaline ceramidase. A mammalian enzyme that hydrolyzes phytoceramide. J Biol Chem 276: 26577-26588.
95. Mao C, Xu R, Szulc ZM, Bielawski J, Becker KP, Bielawska A, et al,. (2003). Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase: an enzyme that preferentially regulates metabolism of very long chain ceramides. J Biol Chem 278: 31184-31191. (Pubitemid 36994634)
96. Mao Z, Sun W, Xu R, Novgorodov S, Szulc ZM, Bielawski J, et al,. (2010). Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells. J Biol Chem 285: 29078-29090.
97. Maor I, Mandel H, Aviram M, (1995). Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-Ketocholesterol. Arterioscler Thromb Vasc Biol 15: 1378-1387.
98. Marchesini N, Luberto C, Hannun YA, (2003). Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem 278: 13775-13783. (Pubitemid 36799914)
99. Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA, (2004). Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem 279: 25101-25111. (Pubitemid 38756759)
100. Marchesini N, Jones JA, Hannun YA, (2007). Confluence induced threonine41/serine45 phospho-beta-catenin dephosphorylation via ceramide-mediated activation of PP1cgamma. Biochim Biophys Acta 1771: 1418-1428.
101. Martelli EA, Toth E, Segre AD, Corsico N, (1967). Mechanism of inhibition of experimental inflammation by antidepressant drugs. Eur J Pharmacol 2: 229-233.
102. Martin SF, Navarro F, Forthoffer N, Navas P, Villalba JM, (2001). Neutral magnesium-dependent sphingomyelinase from liver plasma membrane: purification and inhibition by ubiquinol. J Bioenerg Biomembr 33: 143-153. (Pubitemid 32466390)
103. Martin SF, Gomez-Diaz C, Bello RI, Navas P, Villalba JM, (2003). Inhibition of neutral Mg2+-dependent sphingomyelinase by ubiquinol-mediated plasma membrane electron transport. Protoplasma 221: 109-116. (Pubitemid 36658590)
104. Masson M, Albouz S, Boutry JM, Spezzatti B, Castagna M, Baumann N, (1989). Calmodulin antagonist W-7 inhibits lysosomal sphingomyelinase activity in C6 glioma cells. J Neurochem 52: 1645-1647. (Pubitemid 19109523)
105. Maupas-Schwalm F, Auge N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, et al,. (2004). The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J 18: 1398-1400. (Pubitemid 39561593)
106. Merrill AH, Jr, Sereni AM, Stevens VL, Hannun YA, Bell RM, Kinkade JM, Jr, (1986). Inhibition of phorbol ester-dependent differentiation of human promyelocytic leukemic (HL-60) cells by sphinganine and other long-chain bases. J Biol Chem 261: 12610-12615. (Pubitemid 17204214)
107. Mitsutake S, Tani M, Okino N, Mori K, Ichinose S, Omori A, et al,. (2001). Purification, characterization, molecular cloning, and subcellular distribution of neutral ceramidase of rat kidney. J Biol Chem 276: 26249-26259.
108. Monjusho H, Okino N, Tani M, Maeda M, Yoshida M, Ito M, (2003). A neutral ceramidase homologue from Dictyostelium discoideum exhibits an acidic pH optimum. Biochem J 376: 473-479. (Pubitemid 38010532)
109. Nara F, Tanaka M, Hosoya T, Suzuki-Konagai K, Ogita T, (1999a). Scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima: taxonomy of the producing organism, fermentation, isolation, and physico-chemical properties. J Antibiot 52: 525-530. (Pubitemid 29353749)
110. Nara F, Tanaka M, Masuda-Inoue S, Yamasato Y, Doi-Yoshioka H, Suzuki-Konagai K, et al,. (1999b). Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima. J Antibiot 52: 531-535. (Pubitemid 29353750)
111. Nassogne MC, Lizarraga C, N'Kuli F, Van Bambeke F, Van Binst R, Wallemacq P, et al,. (2004). Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicol Appl Pharmacol 194: 101-110. (Pubitemid 38083364)
112. Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, et al,. (2009). Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 284: 10422-10432.
113. Nikolova-Karakashian MN, Russell RW, Booth RA, Jenden DJ, Merrill AH, Jr, (1997). Sphingomyelin metabolism in rat liver after chronic dietary replacement of choline by N-aminodeanol. J Lipid Res 38: 1764-1770. (Pubitemid 27411268)
114. Nilsson A, (1969). The presence of spingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim Biophys Acta 176: 339-347.
115. Ohlsson L, Palmberg C, Duan RD, Olsson M, Bergman T, Nilsson A, (2007). Purification and characterization of human intestinal neutral ceramidase. Biochimie 89: 950-960. (Pubitemid 47031431)
116. Ohlsson L, Hjelte L, Huhn M, Scholte BJ, Wilke M, Flodstrom-Tullberg M, et al,. (2008). Expression of intestinal and lung alkaline sphingomyelinase and neutral ceramidase in cystic fibrosis f508del transgenic mice. J Pediatr Gastroenterol Nutr 47: 547-554.
117. Okazaki T, Bell RM, Hannun YA, (1989). Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 264: 19076-19080. (Pubitemid 19285812)
118. Okino N, Ichinose S, Omori A, Imayama S, Nakamura T, Ito M, (1999). Molecular cloning, sequencing, and expression of the gene encoding alkaline ceramidase from Pseudomonas aeruginosa. Cloning of a ceramidase homologue from Mycobacterium tuberculosis. J Biol Chem 274: 36616-36622.
119. Okino N, He X, Gatt S, Sandhoff K, Ito M, Schuchman EH, (2003). The reverse activity of human acid ceramidase. J Biol Chem 278: 29948-29953. (Pubitemid 36962383)
120. Okino N, Ikeda R, Ito M, (2010). Expression, purification, and characterization of a recombinant neutral ceramidase from Mycobacterium tuberculosis. Biosci Biotechnol Biochem 74: 316-321.
121. Olsson M, Duan RD, Ohlsson L, Nilsson A, (2004). Rat intestinal ceramidase: purification, properties, and physiological relevance. Am J Physiol Gastrointest Liver Physiol 287: G929-G937. (Pubitemid 39280451)
122. Pappu A, Hostetler KY, (1984). Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem Pharmacol 33: 1639-1644. (Pubitemid 14147790)
123. Pata MO, Wu BX, Bielawski J, Xiong TC, Hannun YA, Ng CK, (2008). Molecular cloning and characterization of OsCDase, a ceramidase enzyme from rice. Plant J 55: 1000-1009.
124. Payne SG, Brindley DN, Guilbert LJ, (1999). Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts. J Cell Physiol 180: 263-270. (Pubitemid 29297203)
125. Peng CH, Huang CN, Hsu SP, Wang CJ, (2006). Penta-acetyl geniposide induce apoptosis in C6 glioma cells by modulating the activation of neutral sphingomyelinase-induced p75 nerve growth factor receptor and protein kinase Cdelta pathway. Mol Pharmacol 70: 997-1004.
126. Philipp S, Puchert M, Adam-Klages S, Tchikov V, Winoto-Morbach S, Mathieu S, et al,. (2010). The Polycomb group protein EED couples TNF receptor 1 to neutral sphingomyelinase. Proc Natl Acad Sci U S A 107: 1112-1117.
127. Pitman MR, Pitson SM, (2010). Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 10: 354-367.
128. Pitsinos EN, Wascholowski V, Karaliota S, Rigou C, Couladouros EA, Giannis A, (2003). Synthesis and evaluation of three novel scyphostatin analogues as neutral sphingomyelinase inhibitors. Chembiochem 4: 1223-1225. (Pubitemid 37462825)
129. Pyne NJ, Pyne S, (2010). Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-503.
130. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, et al,. (2002). Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 516: 47-52. (Pubitemid 34311931)
131. Reagan JW, Jr, Hubbert ML, Shelness GS, (2000). Posttranslational regulation of acid sphingomyelinase in niemann-pick type C1 fibroblasts and free cholesterol-enriched chinese hamster ovary cells. J Biol Chem 275: 38104-38110. (Pubitemid 32004935)
132. Riethmuller J, Anthonysamy J, Serra E, Schwab M, Doring G, Gulbins E, (2009). Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 24: 65-72.
133. Rodriguez-Lafrasse C, Alphonse G, Aloy MT, Ardail D, Gerard JP, Louisot P, et al,. (2002). Increasing endogenous ceramide using inhibitors of sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial injury and apoptotic cell killing. Int J Cancer 101: 589-598.
134. Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C, (2009a). Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew Chem Int Ed Engl 48: 7560-7563.
135. Roth AG, Redmer S, Arenz C, (2009b). Potent inhibition of acid sphingomyelinase by phosphoinositide analogues. Chembiochem 10: 2367-2374.
136. Roth AG, Redmer S, Arenz C, (2010). Development of carbohydrate-derived inhibitors of acid sphingomyelinase. Bioorg Med Chem 18: 939-944.
137. Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, et al,. (2007). Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 8: 35.
138. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, et al,. (2008). Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112: 41-52.
139. Ruckhaberle E, Holtrich U, Engels K, Hanker L, Gatje R, Metzler D, et al,. (2009). Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer. Climacteric 12: 502-513.
140. Rutkute K, Karakashian AA, Giltiay NV, Dobierzewska A, Nikolova-Karakashian MN, (2007). Aging in rat causes hepatic hyperresposiveness to interleukin-1beta which is mediated by neutral sphingomyelinase-2. Hepatology 46: 1166-1176. (Pubitemid 350144781)
141. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, et al,. (2007). The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 6: 1455-1460. (Pubitemid 351590358)
142. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, et al,. (2007a). Acid sphingomyelinase inhibition suppresses lipopolysaccharide- mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice.
143. Sakata A, Yasuda K, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, et al,. (2007b). Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice. Cell Immunol 245: 24-31. (Pubitemid 46776639)
144. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I, (1998). The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 273: 18250-18259. (Pubitemid 28334747)
145. Schuchman EH, (2007). The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis 30: 654-663. (Pubitemid 47559876)
146. Schuchman EH, (2010). Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. FEBS Lett 584: 1895-1900.
147. Schulze H, Schepers U, Sandhoff K, (2007). Overexpression and mass spectrometry analysis of mature human acid ceramidase. Biol Chem 388: 1333-1343. (Pubitemid 350135569)
148. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, et al,. (2001). Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 61: 1233-1240. (Pubitemid 32174448)
149. Shah C, Yang G, Lee I, Bielawski J, Hannun YA, Samad F, (2008). Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283: 13538-13548.
150. Shimizu M, Tada E, Makiyama T, Yasufuku K, Moriyama Y, Fujino H, et al,. (2009). Effects of ceramide, ceramidase inhibition and expression of ceramide kinase on cytosolic phospholipase A2alpha; additional role of ceramide-1-phosphate in phosphorylation and Ca2+ signaling. Cell Signal 21: 440-447.
151. Sitrin RG, Sassanella TM, Petty HR, (2010). An obligate role for membrane-associated neutral sphingomyelinase activity in orienting chemotactic migration of human neutrophils. Am J Respir Cell Mol Biol 44: 205-212.
152. Slater AF, Stefan C, Nobel I, van den Dobbelsteen DJ, Orrenius S, (1995). Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett 82-83: 149-153. (Pubitemid 26054701)
153. Smith EL, Schuchman EH, (2008). The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. Faseb J 22: 3419-3431.
154. Smith AR, Visioli F, Frei B, Hagen TM, (2006). Age-related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide-activated phosphatase 2A. Aging Cell 5: 391-400. (Pubitemid 44322535)
155. Snider AJ, Orr Gandy KA, Obeid LM, (2010). Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 92: 707-715.
156. Sonoda K, Sakamoto T, Yoshikawa H, Ashizuka S, Ohshima Y, Kishihara K, et al,. (1998). Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Invest Ophthalmol Vis Sci 39: 2245-2251. (Pubitemid 28485635)
157. Spence MW, Beed S, Cook HW, (1986). Acid and alkaline ceramidases of rat tissues. Biochem Cell Biol 64: 400-404. (Pubitemid 16089034)
158. Spinedi A, Di Bartolomeo S, Piacentini M, (1999). N-Oleoylethanolamine inhibits glucosylation of natural ceramides in CHP-100 neuroepithelioma cells: possible implications for apoptosis. Biochem Biophys Res Commun 255: 456-459. (Pubitemid 29292281)
159. Stancevic B, Kolesnick R, (2010). Ceramide-rich platforms in transmembrane signaling. FEBS Lett 584: 1728-1740.
160. Stoffel W, Melzner I, (1980). Studies in vitro on the biosynthesis of ceramide and sphingomyelin. A reevaluation of proposed pathways. Hoppe Seylers Z Physiol Chem 361: 755-771. (Pubitemid 10028797)
161. Stoffel W, Jenke B, Holz B, Binczek E, Gunter RH, Knifka J, et al,. (2007). Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am J Pathol 171: 153-161. (Pubitemid 47339235)
162. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, et al,. (2000). Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 192: 601-612.
163. Sturley SL, Patterson MC, Balch W, Liscum L, (2004). The pathophysiology and mechanisms of NP-C disease. Biochim Biophys Acta 1685: 83-87. (Pubitemid 39311812)
164. Sugita M, Willians M, Dulaney JT, Moser HW, (1975). Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim Biophys Acta 398: 125-131.
165. Sun W, Xu R, Hu W, Jin J, Crellin HA, Bielawski J, et al,. (2008). Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol 128: 389-397.
166. Sun W, Hu W, Xu R, Jin J, Szulc ZM, Zhang G, et al,. (2009). Alkaline ceramidase 2 regulates beta1 integrin maturation and cell adhesion. FASEB J 23: 656-666.
167. Tabas I, (1999). Secretory sphingomyelinase. Chem Phys Lipids 102: 123-130. (Pubitemid 29438664)
168. Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ, (2010). Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res 88: 2940-2951.
169. Tada S, Matsushita-Morita M, Suzuki S, Kusumoto K, Kashiwagi Y, (2009). Characterization of a neutral ceramidase orthologue from Aspergillus oryzae. FEMS Microbiol Lett 298: 157-165.
170. Taha TA, Hannun YA, Obeid LM, (2006a). Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131.
171. Taha TA, Mullen TD, Obeid LM, (2006b). A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 1758: 2027-2036. (Pubitemid 44879375)
172. Tani M, Hannun YA, (2007). Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization. J Biol Chem 282: 10047-10056. (Pubitemid 47104605)
173. Tani M, Okino N, Mori K, Tanigawa T, Izu H, Ito M, (2000). Molecular cloning of the full-length cDNA encoding mouse neutral ceramidase. A novel but highly conserved gene family of neutral/alkaline ceramidases. J Biol Chem 275: 11229-11234. (Pubitemid 30212768)
174. Tani M, Iida H, Ito M, (2003). O-glycosylation of mucin-like domain retains the neutral ceramidase on the plasma membranes as a type II integral membrane protein. J Biol Chem 278: 10523-10530. (Pubitemid 36800320)
175. Tani M, Igarashi Y, Ito M, (2005). Involvement of neutral ceramidase in ceramide metabolism at the plasma membrane and in extracellular milieu. J Biol Chem 280: 36592-36600. (Pubitemid 41587735)
176. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, et al,. (2008). Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14: 382-391. (Pubitemid 351499396)
177. Testai FD, Landek MA, Goswami R, Ahmed M, Dawson G, (2004). Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. J Neurochem 89: 636-644. (Pubitemid 38534149)
178. Thomas GH, Tuck-Muller CM, Miller CS, Reynolds LW, (1989). Correction of sphingomyelinase deficiency in Niemann-Pick type C fibroblasts by removal of lipoprotein fraction from culture media. J Inherit Metab Dis 12: 139-151. (Pubitemid 19175095)
179. Usta J, El Bawab S, Roddy P, Szulc ZM, Yusuf HA, et al,. (2001). Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidase. Biochemistry 40: 9657-9668. (Pubitemid 32757905)
180. Watanabe K, Sakuragawa N, Arima M, Satoyoshi E, (1983). Partial purification and properties of acid sphingomyelinase from rat liver. J Lipid Res 24: 596-603.
181. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, et al,. (2009). Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem 109: 1237-1249.
182. Won JS, Im YB, Khan M, Singh AK, Singh I, (2004). The role of neutral sphingomyelinase produced ceramide in lipopolysaccharide-mediated expression of inducible nitric oxide synthase. J Neurochem 88: 583-593. (Pubitemid 38140203)
183. Wu BX, Clarke CJ, Hannun YA, (2010a). Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses. Neuromolecular Med 4: 320-330.
184. Wu BX, Rajagopalan V, Roddy PL, Clarke CJ, Hannun YA, (2010b). Identification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5. J Biol Chem 285: 17993-18002.
185. Xu R, Jin J, Hu W, Sun W, Bielawski J, Szulc Z, et al,. (2006). Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB J 20: 1813-1825. (Pubitemid 44933795)
186. Xu R, Sun W, Jin J, Obeid LM, Mao C, (2010). Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. FASEB J 24: 2507-2515.
187. Yabu T, Shimuzu A, Yamashita M, (2009). A novel mitochondrial sphingomyelinase in zebrafish cells. J Biol Chem 284: 20349-20363.
188. Yada Y, Higuchi K, Imokawa G, (1995). Purification and biochemical characterization of membrane-bound epidermal ceramidases from guinea pig skin. J Biol Chem 270: 12677-12684.
189. Yang J, Qu JM, Summah H, Zhang J, Zhu YG, Jiang HN, (2010). Protective effects of imipramine in murine endotoxin-induced acute lung injury. Eur J Pharmacol 638: 128-133.
190. Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Kominato T, Soeda S, et al,. (2001). Synthesis and evaluation of a difluoromethylene analogue of sphingomyelin as an inhibitor of sphingomyelinase. Bioorg Med Chem Lett 11: 1277-1280. (Pubitemid 32434351)
191. Yoshida Y, Arimoto K, Sato M, Sakuragawa N, Arima M, Satoyoshi E, (1985). Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J Biochem 98: 1669-1679. (Pubitemid 16169203)
192. Yoshimura Y, Okino N, Tani M, Ito M, (2002). Molecular cloning and characterization of a secretory neutral ceramidase of Drosophila melanogaster. J Biochem 132: 229-236. (Pubitemid 34947885)
193. Yoshimura Y, Tani M, Okino N, Iida H, Ito M, (2004). Molecular cloning and functional analysis of zebrafish neutral ceramidase. J Biol Chem 279: 44012-44022. (Pubitemid 39390710)
194. Zeeck A, Schroder K, Frobel K, Grote R, Thiericke R, (1987). The structure of manumycin. I. Characterization, structure elucidation and biological activity. J Antibiot 40: 1530-1540. (Pubitemid 17161585)
195. Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, et al,. (2006). Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-induced PGE2 production. J Biol Chem 281: 24695-24703. (Pubitemid 44274243)
196. Zhu Q, Jin JF, Shan XH, Liu CP, Mao XD, Xu KF, et al,. (2008). Chronic activation of neutral ceramidase protects beta-cells against cytokine-induced apoptosis. Acta Pharmacol Sin 29: 593-599. (Pubitemid 351601443)